Eiger Biopharmaceuticals Inc., of Palo Alto, Calif., said it closed its underwritten public offering of 2.13 million shares of its common stock that included the exercise in full of the underwriter's option to purchase up to 278,212 shares, at $10 each. The offering resulted in net proceeds to the company of approximately $19.5 million.